Department of Gastroenterology, The First Hospital of Jilin University, Changchun, China.
Comput Intell Neurosci. 2022 May 27;2022:6140727. doi: 10.1155/2022/6140727. eCollection 2022.
Celecoxib, a specific cyclooxygenase-2 (COX-2) inhibitor, is a traditional nonsteroidal antipyretic analgesic and anti-inflammatory drug commonly used in clinic, which has inhibitory effect on colorectal cancer, gastric cancer, and other malignant tumors. This study showed that Celecoxib could significantly reverse the invasion and metastasis of gastric cancer and improved the pathological changes due to GC. We collected the clinical specimens to analyze the correlation between the expression of Lnc_AC006548.28, miR-223, and LAMC2. In the mouse model, Celecoxib can slowdown the growth of GC tumor and the occurrence of this effect may depend on Lnc_AC006548.28-miR-223-LAMC2 pathway, in vitro transfection, RT-PCR, western blot, CCK8, small chamber assay, flow cytometry, and immunohistochemistry to retest the protective effect of celecoxib. Our results showed that Celecoxib could reverse invasion and metastasis of gastric cancer through Lnc_AC006548.28-miR-223-LAMC2 pathway.
塞来昔布是一种特异性环氧化酶-2（COX-2）抑制剂，是一种临床常用的传统非甾体解热镇痛抗炎药，对结直肠癌、胃癌等恶性肿瘤有抑制作用。本研究表明塞来昔布能显著逆转胃癌的侵袭转移，并改善 GC 所致的病理变化。我们收集了临床标本，分析了 Lnc_AC006548.28、miR-223 和 LAMC2 的表达之间的相关性。在小鼠模型中，塞来昔布可以减缓 GC 肿瘤的生长，而这种作用的发生可能依赖于 Lnc_AC006548.28-miR-223-LAMC2 通路，通过体外转染、RT-PCR、western blot、CCK8、小室实验、流式细胞术和免疫组化实验再次验证塞来昔布的保护作用。我们的结果表明，塞来昔布可以通过 Lnc_AC006548.28-miR-223-LAMC2 通路逆转胃癌的侵袭转移。
